design
mechanist
unbias
approach
base
chemic
genet
identifi
chemic
start
point
interf
hcv
replic
differenti
strategi
centr
identif
compound
function
distinct
act
tradit
target
antivir
research
field
proteas
rnadepend
rna
use
genotyp
replicon
replic
liver
screen
one
million
compound
bristolmy
squibb
proprietari
collect
high
throughput
mode
use
dual
assay
format
simultan
evalu
replic
relat
flaviviru
bovin
viral
diarrhoea
viru
bvdv
host
cell
cytotox
effici
mean
preliminarili
elimin
compound
without
specif
activ
inhibitor
triag
evalu
biochem
assay
proteas
helicas
polymeras
addit
screen
panel
unrel
virus
iminothiazolidinon
fig
emerg
weak
importantli
specif
inhibitor
hcv
rna
replic
halfmaximum
cytotox
concentr
resist
map
tyrosin
histidin
substitut
residu
protein
hcv
polyprotein
form
basi
extens
seri
chemic
refin
focus
improv
antivir
potenc
broaden
inhibitori
activ
encompass
hcv
genotyp
optim
oral
bioavail
sustain
pharmacokinet
properti
defin
symmetri
import
contributor
antivir
discoveri
preced
disclosur
structur
inform
see
subsequ
identifi
fig
develop
candid
advanc
clinic
studi
lead
identif
preclin
profil
subject
seri
separ
public
compound
potent
hcv
replic
inhibitor
report
far
mean
valu
pm
genotyp
replicon
respect
data
summar
tabl
display
therapeut
index
least
vitro
inact
toward
panel
rna
dna
virus
valu
greater
confirm
specif
hcv
supplementari
tabl
upon
analysi
determin
inhibitori
activ
map
first
amino
acid
hcv
see
antivir
activ
compound
toward
addit
genotyp
assess
use
replicationcompet
replicon
construct
hybrid
entir
code
region
first
amino
acid
genotyp
replac
correspond
sequenc
parent
approach
valid
use
genotypespecif
inhibitor
hcv
summar
tabl
demonstr
potent
inhibitori
activ
toward
genotyp
test
valu
rang
pm
combin
studi
display
additivetosynergist
effect
inhibitor
proteas
nucleosid
alloster
inhibitor
polymeras
indic
potenti
molecul
candid
combin
therapi
hcv
therapeut
agent
data
summar
tabl
supplementari
tabl
significantli
potent
inhibitor
genotyp
infecti
viru
replic
cell
cultur
pm
assay
consid
biolog
relev
vitro
cell
cultur
addit
display
similar
potenc
hela
cell
supplementari
tabl
demonstr
function
inhibit
highli
conserv
differ
cellular
environ
character
resist
profil
genotyp
replicon
cell
maintain
presenc
drug
concentr
time
respect
valu
direct
sequenc
individu
clone
cell
reveal
multipl
chang
first
amino
acid
individu
introduc
wildtyp
replicon
background
display
resist
phenotyp
tabl
show
result
contribut
substitut
resist
transient
replic
assay
use
ensur
observ
resist
phenotyp
caus
inhibitorinduc
substitut
genotyp
identifi
major
resist
variant
wherea
chang
observ
residu
genotyp
addit
substitut
residu
gener
substitut
genotyp
confer
modest
effect
potenc
wherea
substitut
genotyp
associ
much
higher
level
resist
replicon
system
resist
variant
inhibit
vitro
approxim
nm
plasma
concentr
shown
readili
achiev
human
oral
dose
see
indic
singlepoint
substitut
suppress
vivo
notabl
mani
resist
variant
display
reduc
fit
vitro
none
record
major
speci
hcv
sequenc
databas
suggest
natur
select
prevent
domin
advantag
vivo
cyclosporin
structur
relat
compound
inhibit
hcv
replic
vitro
vivo
resist
map
part
domain
ii
iii
assess
potenti
crossresist
sensit
inhibit
cyclosporin
genotyp
replicon
express
rang
substitut
confer
resist
examin
cyclosporin
inhibit
significantli
affect
substitut
studi
valu
compar
observ
wildtyp
genotyp
replicon
supplementari
tabl
confirm
inhibitor
bind
viral
protein
prepar
biotintag
deriv
natur
configur
prolin
stereocentr
diastereom
fig
compound
inhibit
subgenom
viral
rna
replic
genotyp
replicon
nm
inact
toward
replicon
wherea
diastereom
use
control
inact
vitro
exposur
activ
inhibitor
replicon
lysat
pass
streptavidin
agaros
bead
separ
gel
electrophoresi
probe
antibodi
specif
hcv
parallel
experi
use
inact
diastereom
serv
control
could
pull
effici
activ
inhibitor
inact
compound
fig
detect
pulldown
experi
suggest
select
bind
similar
experi
conduct
replicon
express
bvdv
rna
compound
fail
bind
bvdv
hcv
aminoacid
zincbind
phosphoprotein
play
critic
import
enigmat
role
viru
life
substitut
confer
resist
map
domain
protein
incorpor
amphipath
amino
n
termin
residu
thought
anchor
protein
solidst
structur
fragment
domain
residu
hcv
reveal
dimer
complex
pattern
interfaci
recognit
anticip
oligomer
form
postul
sequest
rna
within
replic
uniqu
palindrom
topolog
complement
dimer
structur
protein
locat
resist
substitut
suggest
compound
bind
across
dimer
interfac
proxim
n
terminu
domain
protein
membran
face
opposit
put
rna
bind
domain
specul
may
interfer
precis
dimer
associ
effect
subtl
structur
distort
directli
alloster
interfer
protein
function
circumst
exquisit
inhibitori
potenc
exhibit
vitro
may
relat
disrupt
function
limit
number
dimer
compromis
activ
oligomer
complex
howev
although
hypothesi
allow
amplif
inhibitori
effect
altern
explan
reli
inhibit
two
activ
interact
synergist
studi
requir
defin
exact
mode
action
fulli
convers
compound
use
tool
studi
aspect
hcv
function
viral
replic
investig
may
aid
compound
vitro
profil
similar
restrict
genotyp
exhibit
signific
effect
extens
batteri
vitro
receptor
bind
enzymat
assay
design
assess
promiscu
despit
molecular
mass
dalton
compound
oral
bioavail
four
preclin
speci
plasma
level
readili
achiev
surpass
vitro
distribut
effect
liver
random
doubleblind
placebocontrol
singl
ascendingdos
studi
administ
six
dose
level
healthi
nonhcvinfect
subject
rang
mg
oral
solut
compound
safe
well
toler
mg
clinic
relev
advers
effect
oral
administr
readili
absorb
doseproport
exposur
studi
dose
rang
subject
drug
concentr
greater
proteinbindingadjust
genotyp
measur
replicon
assay
beyond
h
postdos
fig
protein
bindingadjust
figur
deriv
analysi
effect
addit
human
serum
antivir
activ
replicon
presenc
human
serum
pm
ng
genotyp
replicon
pm
ng
genotyop
replicon
random
doubleblind
placebocontrol
singl
ascendingdos
studi
administ
subject
genotyp
chronic
hcv
dose
mg
oral
solut
subject
infect
hcv
genotyp
except
two
subject
mg
three
subject
mg
infect
genotyp
safe
well
toler
hcvinfect
subject
singl
oral
dose
mg
specif
death
seriou
advers
event
discontinu
due
advers
event
clinic
relev
advers
effect
headach
frequent
advers
event
report
four
subject
administr
hcvinfect
subject
mean
plasma
elimin
halflif
rang
h
plasma
drug
level
similar
nonhcvinfect
subject
singl
oral
dose
mg
subject
plasma
concentr
tenfold
protein
bindingadjust
hcv
genotyp
suggest
possibl
daili
administr
plasma
hcv
rna
level
measur
day
administr
mean
declin
time
administr
h
postdos
shown
fig
singl
milligram
dose
produc
mean
reduct
rang
hcv
viral
load
measur
h
drug
administr
mg
dose
produc
greater
antivir
effect
mean
plasma
viral
rna
fall
rang
rang
respect
h
postdos
moreov
mg
dose
result
mean
maxim
hcv
rna
declin
rang
prolong
antivir
respons
observ
two
subject
infect
genotyp
viru
hcv
rna
measur
reach
lower
limit
quantif
less
iu
one
subject
iu
measur
hour
genotyp
analysi
sampl
taken
baselin
hour
postdos
reveal
gener
mark
reduct
viral
load
requir
detect
major
hcv
variant
substitut
observ
aminoacid
posit
identifi
use
vitro
replicon
system
supplementari
tabl
genotyp
genotyp
result
suggest
use
replicon
system
assess
resist
respons
inhibitor
pressur
vivo
followup
sampl
avail
one
subject
reveal
hcv
rna
return
near
baselin
howev
genotyp
analysi
perform
sampl
would
anticip
base
vitro
replicon
potenc
greater
sustain
declin
hcv
rna
observ
subject
infect
genotyp
mean
reduct
rang
mean
reduct
rang
hcv
viral
load
measur
h
mg
dose
respect
subject
infect
genotyp
mean
reduct
rang
mean
reduct
rang
mean
reduct
rang
hcv
viral
load
measur
h
mg
dose
respect
mean
rate
declin
subject
receiv
mg
dose
similar
h
dose
mean
declin
greater
sustain
subject
receiv
mg
subject
receiv
mg
lower
mean
declin
hcv
rna
subject
treat
mg
fig
howev
multipledos
studi
need
defin
optim
dose
rang
maxim
antivir
effect
beyond
first
phase
viral
declin
relationship
maximum
declin
baselin
hcv
rna
drug
pharmacokinet
exposur
explor
use
pearson
correl
coeffici
estim
pearson
correl
coeffici
suggest
maximum
declin
hcv
rna
log
pharmacokinet
exposur
cmax
auc
auc
inf
posit
correl
maximum
declin
hcv
rna
increas
exposur
individu
infect
hcv
consider
risk
develop
liver
cirrhosi
endstag
liver
diseas
hepatocellular
current
standard
care
treatment
hcv
infect
combin
weekli
subcutan
inject
pegyl
conjunct
ribavirin
administ
oral
twice
day
period
rang
week
depend
howev
side
effect
associ
therapeut
regimen
impos
signific
physiolog
psycholog
burden
patient
moreov
sustain
virolog
respons
rate
infect
genotyp
typic
less
ref
directact
hcv
antivir
drug
candid
current
report
latestag
clinic
develop
inhibitor
proteas
polymeras
tradit
antivir
target
although
compound
current
develop
addon
therapi
standard
care
consider
anticip
combin
directact
agent
requir
least
two
mechanist
distinct
inhibitor
suppress
emerg
resist
preliminari
vitro
clinic
profil
inhibitor
describ
paper
make
potenti
valuabl
compon
interferonfre
treatment
regimen
result
provid
clinic
valid
first
new
class
hcv
inhibitor
target
viral
protein
known
enzymat
function
yet
poorli
understood
role
viral
strategi
use
identifi
lead
hcv
inhibitor
optim
molecul
clinic
candid
offer
contemporari
demonstr
effect
approach
drug
discoveri
base
chemic
inde
methodolog
uniqu
applic
target
similar
hcv
precis
function
enigmat
develop
biochem
assay
could
neither
anticip
feasibl
specif
inhibitor
hcv
exhibit
spectrum
genotyp
inhibit
vitro
potenc
efficaci
potenc
singl
oral
dose
chronic
hcvinfect
subject
collect
individu
unpreced
achiev
high
potenc
select
nonmammalian
target
tradit
goal
antivir
medicin
chemistri
past
translat
wider
therapeut
index
clinic
although
preliminari
data
indic
inhibitor
hcv
offer
consider
promis
treatment
hcv
infect
vitro
data
demonstr
addit
synergist
interact
known
hcv
inhibitor
suggest
combin
either
current
standard
care
ultim
emerg
inhibitor
hcv
part
cocktail
directact
antivir
agent
may
lead
therapeut
regimen
better
toler
improv
clinic
vitro
hcv
replicon
system
construct
isol
hcv
replicon
includ
hybrid
replicon
genotyp
coverag
replicon
assay
describ
previous
elabor
supplementari
genotyp
replicon
substitut
gene
substitut
gene
use
adapt
substitut
effici
replicon
replic
genotyp
replicon
substitut
gene
use
adapt
mutat
hcvinfect
clinic
studi
popul
total
subject
receiv
treatment
two
subject
receiv
placebo
subject
select
studi
includ
men
women
age
year
inclus
chronic
infect
hcv
genotyp
treatment
naiv
treatment
nonrespond
defin
subject
receiv
current
standard
care
interferon
andor
ribavirin
continu
detect
hcv
rna
level
includ
relaps
subject
attain
declin
hcv
rna
level
week
stop
treatment
treatmentintoler
subject
defin
subject
unabl
toler
toxic
associ
interferon
andor
ribavirin
receiv
anoth
replic
cofactor
inhibitor
coinfect
human
immunodefici
viru
hepat
b
viru
hcv
genotyp
elig
subject
also
hcv
rna
viral
load
least
iu
document
fibrosur
score
aspart
aminotransferas
platelet
ratio
index
bodi
mass
index
kg
inclus
subject
sign
inform
consent
form
screen
determin
elig
base
medic
histori
physic
examin
measur
vital
sign
electrocardiogram
clinic
laboratori
measur
includ
serolog
determin
valu
hcv
inhibitor
use
fret
assay
describ
luciferas
assay
replicon
cell
maintain
cultur
dmem
fb
inhibitor
serial
dilut
dimethylsulphoxid
dmso
ad
tissu
cultur
plate
costar
catalogu
number
contain
hcv
replicon
cell
seed
approxim
h
previous
tissu
cultur
media
final
concentr
dmso
concentr
shown
previous
nontox
replicon
cell
data
shown
incub
h
cell
plate
test
replic
activ
cytotox
cell
plate
incub
h
celltiterblu
final
concentr
promega
number
determin
cytotox
h
plate
equilibr
ambient
temperatur
gentl
shake
read
cytofluor
seri
persept
biosystem
endpoint
read
perform
excit
nm
emiss
nm
gain
control
well
contain
dmso
set
viabil
percentag
cytotox
determin
concentr
inhibitor
divid
averag
valu
well
contain
compound
averag
valu
well
contain
dmso
read
celltiterblu
media
dye
remov
cell
plate
invert
remain
liquid
blot
paper
towel
replic
activ
hcv
genotyp
cell
line
quantifi
use
renilla
luciferas
thirti
microlitr
renilla
luciferas
lysi
buffer
promega
number
ad
well
plate
incub
gentl
shake
ambient
temperatur
min
forti
microlitr
renilla
luciferas
substrat
promega
number
ad
well
signal
detect
top
count
luminomet
light
emiss
quantif
one
hundr
per
cent
activ
calcul
cell
line
dmso
well
percentag
activ
calcul
concentr
inhibitor
divid
averag
valu
well
contain
compound
averag
valu
well
contain
dmso
human
immunodefici
viru
canin
parainfluenza
viru
suscept
human
immunodefici
viru
canin
parainfluenza
viru
compound
determin
incub
presenc
serial
dilut
compound
recombin
human
immunodefici
virus
express
renilla
luciferas
antivir
activ
evalu
measur
product
luciferas
infect
cell
day
postinfect
use
dual
luciferas
kit
promega
canin
parainfluenza
viru
assay
viral
neuraminidas
activ
use
measur
viral
product
fluoresc
measur
use
ljl
analyst
plate
reader
nm
nm
emiss
bovin
viral
diarrhoea
viru
bvdv
cell
protect
assay
use
assess
specif
describ
briefli
bvdv
place
onto
cell
plate
differ
multipl
infect
day
presenc
absenc
compound
infect
cell
protect
use
posit
control
protect
cytopath
effect
bvdv
bvdv
replicon
cellbas
highthroughput
specif
screen
use
dual
replicon
assay
describ
briefli
bvdv
replicon
cell
hcv
replicon
cell
seed
plate
cell
densiti
per
well
cell
line
dmem
media
contain
fb
incub
overnight
h
compound
serial
dilut
dmso
media
ad
individu
well
cell
plate
incub
day
assay
cytotox
hcv
inhibit
bvdv
inhibit
use
three
separ
compat
assay
method
herp
simplex
viru
hsv
suscept
hsv
virus
compound
determin
use
multicycl
hsv
growth
assay
fifti
plaqu
form
unit
strain
f
strain
suspend
mem
ad
vero
cell
absorpt
h
mem
contain
fb
threefold
serial
dilut
compound
dmso
ad
cell
acyclovir
hsv
inhibitor
includ
control
day
incub
alamar
blue
solut
ad
fluoresc
read
nm
nm
emiss
calcul
influenza
inhibit
influenza
american
type
cultur
collect
number
replic
examin
mdbk
cell
american
type
cultur
collect
number
viral
neuraminidas
activ
assay
measur
influenza
viru
replic
alamar
blue
metabol
use
measur
cytotox
mdbk
cell
resuspend
fb
mem
neuraminidas
assay
viru
product
fb
mem
alamar
bluebas
cytotox
assay
media
without
viru
ad
cell
plate
follow
test
compound
control
compound
plate
contain
viru
incub
h
incub
time
neuraminidas
substrat
ad
fluoresc
gener
viral
neuraminidas
activ
read
nm
nm
emiss
noninfect
cell
assay
plate
contain
compound
dilut
allow
incub
addit
h
alamar
blue
solut
ad
plate
incub
anoth
h
plate
read
nm
nm
emiss
percentag
cytotox
calcul
comparison
control
well
valu
calcul
use
median
effect
equat
positivestrand
virus
human
coronaviru
polioviru
coxsacki
viru
human
rhinoviru
obtain
american
type
cultur
collect
cell
seed
plate
incub
next
day
media
remov
dmem
fb
place
cell
contain
either
counterscreen
viru
multipl
infect
media
alon
dilut
compound
dmso
prepar
dilut
place
dmem
fb
mix
compoundmedia
ad
mediaviru
plate
plate
incub
day
solut
alamar
blue
ad
quantifi
protect
cytotox
cytotox
cell
incub
assay
plate
presenc
serial
dilut
compound
day
cell
day
cell
type
cell
viabil
quantifi
use
either
mt
assay
alamar
blue
assay
cell
vero
hela
cell
microscop
visual
inspect
cell
monolay
also
conduct
period
confirm
cytotox
measur
valu
calcul
use
median
effect
equat
nation
institut
health
genotyp
hcv
fulllength
clone
obtain
j
bukh
genotyp
fragment
obtain
panel
hcvposit
sera
cliniqa
corpor
rna
isol
use
trizol
invitrogen
accord
manufactur
instruct
firststrand
complementari
dna
synthesi
random
primer
superscript
ii
revers
transcriptas
platinum
taq
dna
polymeras
high
fidel
invitrogen
pcr
gene
specif
primer
topo
ta
clone
kit
invitrogen
perform
follow
manufactur
protocol
hybrid
replicon
region
encod
first
amino
acid
differ
genotyp
construct
use
recombin
overlap
pcr
background
clone
verifi
dna
sequenc
analysi
method
select
isol
map
resist
substitut
describ
briefli
hcv
genotyp
replicon
cell
maintain
media
contain
concentr
mg
replicon
cell
similarli
treat
dmso
maintain
control
approxim
week
cell
growth
similar
dmsotreat
control
cell
select
cell
expand
resist
test
analysi
pcr
revers
transcript
resist
profil
replic
level
fit
variant
determin
vitro
transient
replic
assay
introduc
specif
substitut
wildtyp
replicon
compound
inact
diastereom
biotincontain
analogu
use
affin
probe
bind
fig
differ
stereochemistri
prolin
moieti
compound
biotincontain
compound
ad
separ
flask
hcv
replicon
cell
approxim
confluent
cell
incub
normal
growth
condit
approxim
h
cell
remov
edtafre
cell
dissoci
buffer
invitrogen
centrifug
room
temperatur
resuspend
ice
cold
lysi
buffer
mm
trishcl
ph
mm
nacl
mm
edta
complet
proteas
inhibitor
cocktail
roch
appli
scienc
min
nuclei
remov
centrifug
min
portion
supernat
save
input
control
immunoblot
analysi
see
remaind
mix
bead
sigma
incub
sever
hour
gentl
rock
bead
pellet
brief
centrifug
wash
sever
time
lysi
buffer
resuspend
sd
gel
load
buffer
heat
min
brief
spin
min
supernat
electrophores
criterion
gel
biorad
laboratori
follow
manufactur
recommend
procedur
protein
transfer
nitrocellulos
analys
immunoblot
primari
antibodi
direct
hcv
hrpconjug
secondari
antibodi
sigma
antibodi
complex
detect
chemiluminesc
western
lightn
chemiluminesc
reagent
plu
kit
perkinelm
follow
manufactur
instruct
clinic
trial
conduct
accord
good
clinic
practic
defin
intern
confer
harmonis
accord
ethic
principl
underli
european
union
direct
unit
state
code
feder
regul
titl
part
protocol
subject
inform
consent
receiv
institut
review
boardindepend
ethic
committe
approvalfavour
opinion
initi
studi
freeli
given
written
inform
consent
obtain
everi
subject
particip
clinic
studi
subject
could
treatmentna
experienc
men
women
year
age
hcv
rna
iu
noncirrhot
compens
liver
diseas
plasma
sampl
obtain
variou
time
analys
valid
liquid
chromatographi
tandem
mass
spectrometri
assay
individu
subject
pharmacokinet
paramet
valu
deriv
noncompartment
method
valid
pharmacokinet
analysi
programm
plasma
hcv
rna
level
determin
use
roch
taqman
hcv
qpcr
quantit
assay
limit
detect
iu
rang
quantif
iu
sampl
analys
central
laboratori
